FT516 + Rituximab + Obinutuzumab + Cyclophosphamide + Fludarabine + IL-2 + Bendamustine
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia, B-cell Lymphoma
Trial Timeline
Oct 4, 2019 → Oct 23, 2023
NCT ID
NCT04023071About FT516 + Rituximab + Obinutuzumab + Cyclophosphamide + Fludarabine + IL-2 + Bendamustine
FT516 + Rituximab + Obinutuzumab + Cyclophosphamide + Fludarabine + IL-2 + Bendamustine is a phase 1 stage product being developed by Fate Therapeutics for Acute Myelogenous Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04023071. Target conditions include Acute Myelogenous Leukemia, B-cell Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04023071 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myelogenous Leukemia